Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 29 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g antirheumatic agents; Non-steroidal antiinflammatory drugs (nsaids)
Patents for A61P 29 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g antirheumatic agents; Non-steroidal antiinflammatory drugs (nsaids) (127,169)
12/2000
12/27/2000EP1061911A2 Novel methods for treating disorders in which docosahexaenoic acid (dha) levels are affected
12/27/2000EP1061812A1 Food products having enhanced cocoa polyphenol content and processes for producing same
12/27/2000EP1061805A1 Regulation of endogenous gene expression in cells using zinc finger proteins
12/27/2000EP0882015B1 Diphenyl stilbenes as prodrugs to cox-2 inhibitors
12/27/2000EP0821666B1 Derivatives of succinamide and their use as metalloproteinase inhibitors
12/27/2000EP0756481B1 17$g(b)-ARYL-4-AZA-STEROID DERIVATIVES
12/27/2000CN1278263A 2,3-diaryl-pyrazolo [1,5-B] pyridazines derivatives, their prepn. and use as cyclooxygenase 2 (cox-2) inhibitors
12/27/2000CN1278258A Azaring-ether derivatives and their use as nicotinic ach receptor modulators
12/27/2000CN1278250A Vitronectin receptor antagonists
12/27/2000CN1278247A Alpha-hydroxy, amino and -fluoro derivatives of beta-sulphenyl hydroxamic acids matrix metalloproteinases inhibitors
12/27/2000CN1278245A Malonic acid based matric metalloproteinase inhibitors
12/27/2000CN1278244A Dipeptide nitriles
12/27/2000CN1278158A Synergistic analgestic combination of opioid analgsic and cyclooxygenase-2
12/27/2000CN1277870A Traditional Chinese medicine (Xianqi) mixture for treating chronic bronchitis
12/27/2000CN1277841A Quick absorption liquid composite
12/27/2000CN1059905C Rapamycin hydroxyesters, process for their preparation and pharmaceutical compositions containing them
12/26/2000US6166185 Antibodies to human TIE-2 ligands
12/26/2000US6166087 Immunosuppresants, antiinflammatory agents, antitumor agents;applying to mucous membranes
12/26/2000US6166083 Suckable flurbiprofen lozenges for treatment of sore throat
12/26/2000US6166064 Antiinflammatory agents; antiarthritic agents
12/26/2000US6166060 Antihistamines; sleep disorders; central nervous system disorders
12/26/2000US6166048 Pharmaceutical compositions for inhibition of cytokine production and secretion
12/26/2000US6166023 1,5- and 3-O-substituted 1H-indazoles having anti-asthmatic, anti-allergic, anti-inflammatory, immunomodulating and neuroprotective action, process for their preparation and their use as medicaments
12/26/2000US6166005 Heterocyclic metalloprotease inhibitors
12/26/2000US6165996 Compounds with chelation affinity selectivity for first transition series elements: use in medical therapy and diagnosis
12/26/2000US6165983 Use of collagen for the treatment of degenerative articular processes
12/26/2000US6165771 Compounds
12/26/2000US6165766 Amino acid sequence of serine/threonine protein kinase; anticarcinogenic/antiarthritic/antiinflammatory agents; treatment of osteoporosis, adult respiratory disease syndrome, inflammatory bowel disease, eating disorders; diagnosis
12/26/2000US6165763 Nucleotide and amino acid sequences of enzyme from streptococcus; for drug screening of bacteriostats and bactericides
12/26/2000US6165751 HLDAT86 polynucleotides
12/26/2000US6165732 Drug screening by using lipid bilayer that has potassium- or chloride-selective channel formed from polpeptide of bcl-2 family, contacting compound with bilayer, and determining ion-selectivity of channel; indicates agonist or antagonist
12/26/2000US6165506 A solid dose nanoparticulate naproxen formulation having a high rate of dissolution comprising a naproxen having specific particle size, polyvinylpyrrolidone adsorbed on the surface and an alkali agent to increase the dissolution rate
12/25/2000CA2475401A1 Method for the preparation of citalopram
12/21/2000WO2000077255A1 49 human secreted proteins
12/21/2000WO2000077246A2 A METHOD FOR IDENTIFYING A DRUG CANDIDATE HAVING AN INHIBITORY ACTION ON FVII-TF ACTIVITY, AND FVIIa/TF ACTIVITY INHIBITING COMPOUNDS
12/21/2000WO2000077237A1 49 human secreted proteins
12/21/2000WO2000077226A1 22025, a novel human cyclic nucleotide phosphodiesterase
12/21/2000WO2000077207A2 Nucleic acid encoding proteins involved in protein degradation, products and methods related thereto
12/21/2000WO2000077198A2 Identification and molecular characterisation of proteins, expressed in the tick salivary glands
12/21/2000WO2000077191A1 Tumor necrosis factor related receptor, tr6
12/21/2000WO2000077179A2 Human poly(adp-ribose) polymerase 2 materials and methods
12/21/2000WO2000077173A1 42 human secreted proteins
12/21/2000WO2000077166A2 Gene expression modulated in gastrointestinal inflammation
12/21/2000WO2000077040A2 Human intracellular signaling molecules
12/21/2000WO2000077023A1 48 human secreted proteins
12/21/2000WO2000077022A1 50 human secreted proteins
12/21/2000WO2000077021A1 48 human secreted proteins
12/21/2000WO2000077018A2 Purine derivatives
12/21/2000WO2000076980A1 Novel nitrogen-contaiing heterocyclic derivatives or salts thereof
12/21/2000WO2000076972A1 N-cyclopentyl modulators of chemokine receptor activity
12/21/2000WO2000076958A2 Mono- and disubstituted 3-propyl gamma-aminobutyric acids
12/21/2000WO2000076550A2 Carrier-drug conjugate
12/21/2000WO2000076532A1 νO-CONOPEPTIDES AND THEIR USE AS LOCAL ANESTHETICS
12/21/2000WO2000076531A1 47 human secreted proteins
12/21/2000WO2000076530A1 49 human secreted proteins
12/21/2000WO2000076528A2 Pharmaceutical preparation containing proteins
12/21/2000WO2000076503A1 1-(4-sulfamylaryl)-3-substituted-5-aryl-2-pyrazolines as inhibitors of cyclooxygenase-2
12/21/2000WO2000076478A1 Controlled release and taste masking oral pharmaceutical compositions
12/21/2000WO2000076315A1 Transdermally delivered aspirin
12/21/2000WO2000053628A3 Genes encoding human potassium channel proteins
12/21/2000WO2000046240A3 Polypeptides involved in immune response
12/21/2000WO2000045834A3 Use of aerosolized cyclosporine for prevention and treatment of pulmonary disease
12/21/2000WO2000045791A3 Method for controlling liposome size
12/21/2000WO2000044710A3 Acetylenic aryl sulfonamide and phosphinic acid amide hydroxamic acid tace inhibitors
12/21/2000WO2000044709A3 ACETYLENIC α-AMINO ACID-BASED SULFONAMIDE HYDROXAMIC ACID TACE INHIBITORS
12/21/2000WO2000044361A3 Highly purified ethyl epa and other epa derivatives for psychiatric and neurological disorders
12/21/2000WO2000031094A3 Benzylglycosylamides as inhibitors of smooth muscle cell proliferation
12/21/2000DE19927689A1 Oral dosage formulation containing tramadol and diclofenac, useful for treating pain, contains the active ingredients in separate subunits
12/21/2000DE19927574A1 Increasing content of flavonoids and phenols in plants, useful for e.g. preventing cardiovascular disease, by reducing activity of flavanone-3-hydroxylase
12/21/2000DE19925739A1 Therapeutikum mit einem Botulinum-Neurotoxin Agent with a botulinum neurotoxin
12/21/2000CA2689997A1 Mono- and disubstituted 3-propyl gamma-aminobutyric acids
12/21/2000CA2391364A1 47 human secreted proteins
12/21/2000CA2390946A1 49 human secreted proteins
12/21/2000CA2387696A1 48 human secreted proteins
12/21/2000CA2383048A1 49 human secreted proteins
12/21/2000CA2382769A1 42 human secreted proteins
12/21/2000CA2382748A1 50 human secreted proteins
12/21/2000CA2382743A1 48 human secreted proteins
12/21/2000CA2382735A1 49 human secreted proteins
12/21/2000CA2377153A1 1-(4-sulfamylaryl)-3-substituted-5-aryl-2-pyrazolines as inhibitors of cyclooxygenase-2
12/21/2000CA2376717A1 Human poly(adp-ribose) polymerase 2 materials and methods
12/21/2000CA2376667A1 Gene expression modulated in gastrointestinal inflammation
12/21/2000CA2376421A1 Identification and molecular characterisation of proteins, expressed in the tick salivary glands
12/21/2000CA2376357A1 .mu.o-conopeptides and their use as local anesthetics
12/21/2000CA2374909A1 Human intracellular signaling molecules
12/21/2000CA2340120A1 Transdermally delivered aspirin
12/20/2000EP1061077A1 Novel pyridazine derivatives and drugs containing the same as the active ingredient
12/20/2000EP1060193A2 Cd147 binding molecules as therapeutics
12/20/2000EP1060188A1 Cholenic acid amides and pharmaceutical compositions thereof
12/20/2000EP1060181A1 Substituted pyrrolobenzimidazoles for treating inflammatory diseases
12/20/2000EP1060175A2 Tryptase inhibitors
12/20/2000EP1060173A2 Benzazine derivatives phosphodiesterase 4 inhibitors
12/20/2000EP1060171A2 Tryptase inhibitors
12/20/2000EP1060164A1 Meta-azacyclic amino benzoic acid compounds and derivatives thereof being integrin antagonists
12/20/2000EP1060161A1 Matrix metalloproteinase inhibitors
12/20/2000EP1059934A2 Matrix protein compositions for wound healing
12/20/2000EP1059930A1 Compositions comprising valerian extracts, isovaleric acid or derivatives thereof with a nsaid
12/20/2000EP1059916A1 Extended release dosage form
12/20/2000EP1059913A1 Emulsion preconcentrates containing cyclosporin or a macrolide
12/20/2000EP0938309A4 Methods for in vivo reduction of iron levels and compositions useful therefor
1 ... 1028 1029 1030 1031 1032 1033 1034 1035 1036 1037 1038 1039 1040 1041 1042 1043 1044 1045 1046 1047 1048 ... 1272